Related Experiment Video

Updated: Aug 17, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Rationale for the use of angiotensin II receptor blockers in patients with left ventricular dysfunction (part I of

T Barry Levine1, Arlene B Levine

  • 1Division of Cardiology, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212-4772, USA. blevine@wpahs.org

Clinical Cardiology
|June 24, 2005
PubMed

Insights

Angiotensin II receptor blockers (ARBs) offer a promising alternative for heart failure (HF) patients, potentially improving outcomes where ACE inhibitors fall short. ARBs provide more complete renin-angiotensin system blockade and are better tolerated, addressing limitations of current HF therapies.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (HF) affects nearly 5 million US individuals, with increasing prevalence.
  • Standard HF treatments like ACE inhibitors and beta blockers reduce morbidity and mortality but have limitations.
  • Unacceptable morbidity and mortality rates persist despite current therapies.

Purpose of the Study:

  • To evaluate the clinical effects of Angiotensin II Receptor Blockers (ARBs) in patients with heart failure (HF).
  • To address limitations of ACE inhibitors, including intolerance (e.g., cough) and incomplete renin-angiotensin system (RAS) blockade.
  • To explore ARBs' potential for more complete RAS blockade via receptor-level interference.

Main Methods:

  • Clinical trials were reviewed to assess the efficacy of ARBs in HF patients.
  • Comparison of ARBs with ACE inhibitors regarding tolerability and mechanism of action.
  • Evaluation of ARBs' impact on HF symptoms and function.

Main Results:

  • ARBs may achieve more complete RAS blockade than ACE inhibitors.
  • ARBs are better tolerated than ACE inhibitors, with fewer adverse effects like cough.
  • Clinical trials indicate ARBs improve symptoms and function in HF patients.

Conclusions:

  • ARBs present a strong rationale for use in heart failure management.
  • They offer an alternative for patients intolerant to ACE inhibitors.
  • ARBs may provide superior RAS blockade and improved clinical outcomes in HF.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...